摘要
Abstract Head and neck dermatitis (HND) in patients with atopic dermatitis (AD) treated with dupilumab is increasingly recognized, leading to terms such as ‘dupilumab-associated HND’ (DAHND). However, it is unclear whether DAHND is new-onset dermatitis or whether it is lack of drug effectiveness in the head and neck area. To assess the risk of HND in patients with AD treated with newer therapies, we undertook a systematic review. Embase, MEDLINE, Scopus and Web of Science search results were screened according to the PIO criteria (population: patients with AD, intervention: biologics or Janus kinase inhibitors, outcome: HND). The search was carried out on 11 June 2024 according to the PRISMA guidelines, and the study was registered with PROSPERO. Case reports and reviews were excluded. Study quality was assessed with the Joanna Briggs Institute and National Heart, Lung, and Blood Institute tools and analysis was by narrative synthesis. The effect of various treatments on HND severity was classified as improved/resolved, recalcitrant/exacerbated, de novo, or unspecified. In total, 401 publications were screened, and 43 studies were selected (10 865 patients with AD). Most data related to dupilumab treatment (86% studies), which resulted in de novo HND in 3.7% of cases (81 of 2193), recalcitrant/exacerbated HND in 14.3% (415 of 2899) and unspecified HND in 7.8% (181 of 2330). Improved/resolved HND was not reported per patient, but in one trial, the median time to 75% improvement in HND was 57 days for dupilumab (n = 238) vs. 29 days for abrocitinib 200 mg. However, by week 16 the improvements in Eczema Area and Severity Index for patients with HND were similar (74.2 vs. 76.6%, respectively). Adverse HND was also reported for tralokinumab (3 of 49, 6%) and baricitinib (two of three, 67%). Antifungals, topical anti-inflammatories and systemic combination therapy were reported as treatments. Although eight studies trialled azoles, only one DAHND study (n = 25) showed increased Malassezia (by specific IgE, M-IgE), which reduced with treatment. Itraconazole led to clinical improvement in all cases that recurred on withdrawal. Twelve of 14 patch-tested cases of DAHND showed improvement with avoidance of patch test positives. In three studies, switching from dupilumab to Janus kinase inhibitor (JAKi) monotherapy improved or resolved HND in 94% (31 of 33) of patients. In studies that recorded HND improvement overall, this was generally less pronounced than other anatomical areas, highlighting the head and neck as being more resistant to treatment. Despite the limitations, by synthesizing data from different studies, we estimate that approximately 74% of cases with pre-existing HND treated with dupilumab improve on therapy. However, our analysis also suggests that dupilumab may be associated with worsened HND in 18% of cases. Early results suggest triazole antifungals may offer temporary improvement, but that JAKis are effective to treat HND complicating biologic treatment. Future studies should compare head and neck outcomes between different biologics and JAKis. This will help improve treatment decisions for patients where HND is of particular concern.